IL2 and capillary leak syndrome: High-dose interleukin-2 (IL-2) therapy, approved for advanced melanoma and renal cell carcinoma in 1998 [20,21], demonstrated some activity in pretreated pediatric sarcoma [22], though its use was restricted due to the high incidence of severe toxicity (cytokine-induced capillary leak syndrome [23]).